Study of LY5830966 for myelofibrosis after JAK inhibitor treatment
Part of Blood & lymphatic clinical trials.
This study tests a new drug called LY5830966 for people with myelofibrosis whose disease has not responded to or has returned after treatment with a type I JAK2 inhibitor. The drug aims to help reduce symptoms and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.
- Your spleen is enlarged (at least 450 cubic centimeters) and you have symptoms like fatigue, night sweats, or bone pain (score of at least 10 on a symptom scale, or at least 2 symptoms with scores of 3 or higher).
- You have previously been treated with a type I JAK2 inhibitor (e.g., ruxolitinib) and it either did not work or stopped working.
- Your blood counts and organ function meet certain minimum levels (e.g., platelet count at least 75,000, adequate kidney and liver function).
- You are not currently taking strong medications that interact with the study drug, and you have not had recent surgery to remove your spleen or radiation to the spleen.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called tasquinimod, either alone or combined with ruxolitinib, for people with myelofibrosis. It's for patients who haven't gotten enough help from standard treatments or who can't take them.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
This trial is testing a new drug called WJ01024, which may help treat myelofibrosis. It can be taken alone or with ruxolitinib, a standard treatment for this condition. The study checks safety and how well it works.
This trial tests a new tablet, Flonoltinib, for people with medium-to-high risk myelofibrosis whose prior JAK inhibitor treatment stopped working, caused side effects, or wasn't tolerated. The goal is to see if this new drug can help reduce spleen size and improve symptoms.
Hear when a new Primary Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.